Author:
Gore Martin E.,Hariharan Subramanian,Porta Camillo,Bracarda Sergio,Hawkins Robert,Bjarnason Georg A.,Oudard Stéphane,Lee Se-Hoon,Carteni Giacomo,Nieto Alejandra,Yuan Jinyu,Szczylik Cezary
Reference30 articles.
1. Sunitinib: from rational design to clinical efficacy;Chow;J Clin Oncol.,2007
2. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer;Abrams;Mol Cancer Ther.,2003
3. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo;O'Farrell;Blood.,2003
4. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients;O'Farrell;Clin Cancer Res.,2003
5. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship;Mendel;Clin Cancer Res.,2003
Cited by
129 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献